News and Community

Ai Drug Discovery, Brain-penetrant Therapy, Healthcare Technology, Iam217, Iambic, Kif18a Inhibitor, Solid Tumors, Triple-negative Breast Cancer

October 6, 2026

Iambic Announces IND Submission for IAM217, a Potentially Brain-Penetrant KIF18A Inhibitor and Second AI-Discovered Candidate